Preferred Name |
fostriecin |
|
Synonyms |
phosphotrienin |
|
Definitions |
An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in protein-associated strand breaks and impaired DNA and RNA synthesis in various malignant cell types. This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1372" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1372" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000041703 |
|
altLabel |
phosphotrienin FST 2H-pyran-2-one,5,6-dihydro-6-(3,6,13-trihydroxy-3-methyl-4-(phosphonooxy)-1,7,9,11,-tridecatetraenyl)-,trans |
|
CAS Registry |
87810-56-8 |
|
cui |
C0118175 |
|
definition |
An anti-tumor antibiotic isolated from the bacterium Streptomyces pulveraceus. Fostriecin inhibits topoisomerase II catalytic activity, resulting in protein-associated strand breaks and impaired DNA and RNA synthesis in various malignant cell types. This agent also inhibits serine/threonine protein phosphatase type 2A in some tumor cell types, thereby interfering with cellular proliferation and differentiation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1372" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1372" NCI Thesaurus) |
|
IND Code |
39667 |
|
Legacy PDQ ID |
4870 |
|
NCI ID |
C1372 |
|
notation |
CDR0000041703 |
|
NSC Code |
339638 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
fostriecin |
|
tui |
T109 T121 |